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Abstract
Introduction. During COVID-19 global pandemic, tracheostomy is often performed on critically ill COVID-19 patients. There is no available data on the survival rate
of critically ill COVID-19 patients on tracheostomy in Indonesia. This study aimed to find the survival rate of critically ill COVID-19 patients on tracheostomy in
Indonesia.
Methods. A descriptive survival analysis study enrolled critically ill COVID-19 patients in RSUI who underwent a tracheostomy procedure. Baseline data, including
clinical characteristics and laboratory findings before tracheostomy, were recorded. Survival analysis was conducted using the Kaplan-Meier plot.
Results. Forty-two subjects were enrolled in thestudy: 25 males (59.5%) and 17 females (40.5%). The median age was 57 (26 – 72) years. Subjectswith diabetes mellitus
or hypertension were 78.6% and 78.6% with BMI >25 kg/m2. The mean duration of intubation was 16.24 ±7.62 days, the median duration of tracheostomy before the
outcome was 8 (0 – 53) days. There were 9.5% of subjects survived and were discharged. The median survival time was 8 (0 – 53). In the first 15 days after tracheostomy
procedures, those who were deceased were 75% of the subjects.
Conclusion. In this study, the survival rate of critically ill COVID-19 patients on tracheostomy remains low. Another study to evaluate the cause of the low survival rate
of critically ill patients with COVID-19 on tracheostomy is required.
Key words: Tracheostomy, COVID–19, Survival rate

Introduction
Coronavirus disease 2019 (COVID-19) is the largest pandemic in the
decade. Patients with COVID-19 experience symptoms of viral
pneumonia,1 19% of which will experience severe symptoms,1,2 and 1015% with severe symptoms will need mechanical ventilation.1,3 Until
October 2021, there have been 4.24 million COVID-19 cases in
Indonesia, and 143 thousand died.4In this pandemic era, tracheostomy
is one of the solutions to ease patients' breathing, reduce respiratory dead
space, expedite ventilator weaning and facilitate the suction of build-up
mucus in the airway.1,5 However, there were questions on the
appropriate timing of tracheostomy, benefits, backs, and survival rate.1,5
The study on tracheostomy on COVID-19 patients remains sparse and
often insufficient for medical professionals for decision making. The
accuracy – of the primetime – to proceed with tracheostomy in COVID19 patients remains controversial. Some suggest tracheostomy to be
performed between 7 to 14 days since intubation.5 Study of Rozenblat et
al. enrolling 30 COVID-19 patients in Israel showed that the mean
survival time of critically ill COVID-19 patients was 41 ±3.1 days. The
number is higher than the mean survival rate of 127 intubated patients,
21 ±2.2 days.1 A study on 1890 tracheostomized COVID-19 patients in
Spain by Martin-Villares et al. showed that 383 (23.7%) died after a onemonth follow-up.5

However, no study in Indonesia focuses on the survival of
tracheotomized critically ill COVID-19 patients. The present study
investigated the survival rate of critically ill COVID-19 patients on
tracheostomy in Indonesia.
Method
This study enrolled 42 tracheostomized critically ill COVID-19 patients
in Universitas Indonesia Hospital (Rumah Sakit Universitas Indonesia,
RSUI) from March 2020 to September 2021. A consecutive sampling
method was used. A single general surgeon performed all the
tracheostomy procedures. Eligible subjects were adults (age >18 years
old); confirmed COVID-19 positive by SARS-CoV-2 RT-PCR
(reverse-transcriptase polymerase chain reaction); met the criteria for
critically ill according to Guideline for Covid–19 Management 3rd
edition; namely those with acute respiratory distress syndrome (ARDS),
sepsis, or septic shock. Patients who remained inpatient or deceased
during the tracheostomy procedure were excluded.
Baseline data were recorded based on electronic medical records,
namely age, gender, body mass index, glycemic status, hypertensive
status, vital signs before tracheostomy procedure, ventilator mode,
PEEP (positive end-expiratory pressure), subcutaneous
emphysema/pneumomediastinum status, usage of vasoconstrictors,
duration of intubation to tracheostomy, duration of tracheostomy.
8
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Recorded laboratory data were hemoglobin content; leukocytes count,
neutrophils count, lymphocytes count, platelet count, blood pH, blood
PaO2, blood PaCO2 before tracheostomy. All laboratory tests were
conducted in the laboratory of RSUI.
These data were statistically analyzed using SPSS v.25 (IBM, North
Castel, NY, USA). Descriptive survival analysis was performed using
the Kaplan-Meier plot. The Committee of Ethics, Rumah Sakit
Universitas Indonesia approved this study (REC number S070/KETLIT/RSUI/XI/2021).
Results
A higher proportion of the subjects was male (59.5%). The median age
was 57 years old, with the youngest being 26 and the oldest being 72.
Most subjects had high body mass index (25–29.9: 31%; 30–34.9: 31%;
35–39.9: 14.3%; >40: 2.4%). Subjects with hypertension or diabetes
mellitus were 78.6%. Most subjects were mechanically ventilated using
PSIMV mode (88.1%). The median leukocyte count was higher than
normal (18,385 cells/mm3). The neutrophil-lymphocyte ratio's median
was also increased (20.11). Almost no reintubation occurred in the
subjects (4.8%). Most patients used vasoconstrictor (90.5%). The most
common was norepinephrine (47.6%). The mean duration of intubation
before tracheostomy was 16.24 ±7.62. The median tracheostomy
duration before the outcome was eight days, with the lowest being zeroday, and the highest was 53 days. More than half of tracheostomy
procedures were performed at the bedside (61.9%). 4 out of 42 (9.5%)
patients survived and were discharged after follow-up (9.5%). The detail
is shown in table 1.

Subcutaneous emphysema or
pneumomediastinum, n (%)
Yes
No
Hb (g/dL), mean ±SD
Leukocyte (cells/mm3), median (min-max)
Neutrophils (%), median (min-max)
Lymphocytes (%), median (min-max)
Neutrophil-lymphocyte ratio, median (minmax)
Platelet (*10^3/µl), median (min-max)
Blood pH, median (min-max)
PaO2 (mmHg), median (min-max)
PaCO2 (mmHg), mean ±SD
Reintubation, n (%)
Yes
No
Vasoconstrictor, n (%)
Norepinephrine (NE)
Dobutamine (DB)
NE and DB
No vasoconstrictor
Duration of intubation before tracheostomy,
(days), mean ±SD
Duration of tracheostomy (days), median (minmax)
Tracheostomy location, n (%)
Bedside
Operating theatre
Outcome
Died
Discharged

18 (42.9)
24 (57.1)
11.16 ±2.07
18385 (3780 – 37190)
89.6 (36.2 – 97.9)
4.5 (0.4 – 33.7)
20.11 (1.63 – 244.75)
264.5 (86 – 711)
7.383 (7.138 – 7.519)
94.25 (52.30 – 276.90)
40.46 ±11.73
2 (4.8)
40 (95.2)
20 (47.6)
5 (11.9)
13 (31)
4 (9.5)
16.24 ±7.62
8 (0 – 53)

26 (61.9)
16 (38.1)
38 (90.5)
4 (9.5)

The median survival time of critically ill tracheotomized patients in this
study was eight days. 75% of patients died in the first 15 days of
tracheostomy, as seen in Figure 1 and Table 2.

Table 1. Baseline data
Number of subjects, n
Gender, n (%)
Male
Female
Age (years), median (min-max)
Body mass index (kg/m2), n (%)
<18.5
18.5 – 24.9
25 – 29.9
30 – 34.9
35 – 39.9
≥40
Diabetes mellitus, n (%)
Yes
No
Hypertension, n (%)
Yes
No
Comorbidities (hypertension or DM), n (%)
Yes
No
Systolic blood pressure (mmHg), median (minmax)
Diastolic blood pressure (mmHg), mean ±SD
Heart rate (bpm), mean ±SD
Temperature (°C), median (min-max)
Peripheral O2 Saturation (%), median (minmax)
Ventilator mode, n (%)
Spontaneous (SPONT)
Pressure-controlled mandatory ventilation
(PCMV)
Volume-controlled mandatory ventilation
(VCMV)
Pressure synchronized intermittent
mandatory ventilation (PSIMV)
Airway pressure release ventilation
(APRV)
PEEP (cmH2O), median (min-max)

42

Table 2. The survival rates
25 (59.5)
17 (40.5)
57 (26 – 72)
1 (2.4)
8 (19)
13 (31)
13 (31)
6 (14.3)
1 (2.4)

75% of subjects survived
50% of subjects survived
25% of subjects survived
Median (min-max) survival time

Day
4
8
15
8 (0 – 53)

24 (57.1)
18 (42.9)
23 (54.8)
19 (45.2)
33 (78.6)
9 (21.4)
121.50 (69 – 153)
71.29 ±9.99
93.48 ±19.33
37.1 (36.0 – 38.9)
99 (72 – 100)

1 (2.4)
2 (4.8)

Figure 1. Kaplan-Meier plot for the duration of tracheostomy

Discussion

1 (2.4)
37 (88.1)
1 (2.4)
8 (5 – 10)

At the end of this study, the survival rate of critically ill COVID-19
patients on tracheostomy was 9.5%, considerably lower than in other
studies. A similar study in Israel on 30 tracheotomized COVID-19
patients found the survival rate after one-month follow-up was 60%1,
despite having similar baseline characteristics.
9
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The mean survival time in the mentioned study was 41 ±3 days,
considerably longer than our study, median survival time 8 (0–53) days.
A cohort study of 1890 COVID-19 patients who underwent
tracheostomy showed 52.1% of patients achieved weaning, 24.2% still
in mechanical ventilation, and 23.7% died from COVID-19 after onemonth follow-up.5 Whereas, 50% of patients in this study passed away
eight days after tracheostomy was performed.

survival rate of critically ill COVID-19 patients on tracheostomy should
be conducted.

Mortality in those with COVID-19 is associated with several factors. A
study in Brazil by de Souza et al. on 44,128 hospitalized COVID-19
patients showed that older age increased mortality risk.7 Age 40 – 60; 60
– 80; >80 had hazard ratio (HR) of 1.37 (CI95%: 1.27–1.48); 2.19
(CI95%: 2.19–2.52); and 3.87 (CI95%: 3.60–4.17) respectively.7
Mechanical ventilation was also related to increased mortality (HR:3.88;
CI95%: 3.68–4.09).7 Low oxygen saturation (HR: 1.27; CI95%: 1.23–
1.32), ICU admission (HR: 1.25; CI95%: 1.21–1.30), respiratory
distress (HR: 1.20; CI95%: 1.16–1.24), male (HR: 1.10; CI95%: 1.07–
1.13), diabetes mellitus (HR: 1.11; CI95%: 1.07–1.14), other
comorbidities (HR: 1.05; CI95%: 1.02–1.09) were associated with
increased COVID-19 mortality.7 Similar findings were discovered by
Dessie and Zewotir et al. In their meta-analysis and systematic review of
42 studies and 423,117 COVID-19 patients. It was found that old age
(pHR: 1.31; CI95%: 1.11–1.51), male (pHR: 1.24; CI95%: 1.07–1.83),
and smoking (pOR: 1.42; CI95%: 1.01–1.83) associated with increased
mortality.8 Diabetes mellitus, hypertension, cerebrovascular disease, a
chronic obstructive pulmonary disorder, and acute kidney injury also
increased COVID-19 patients' mortality significantly.8 Increased NLR
was correlated to increased mortality in COVID-19 patients.9,10 A cohort
study in China showed that mortality risk increased 10 percent for every
one-point increase.10
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